Dr Reddy’s Laboratories Ltd. has received approval from the US Food and Drug Administration (FDA) to launch doxorubicin hydrochloride liposome injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market. The US FDA approval is an outcome of extensive collaboration with the company’s partner, Natco Pharma Ltd., on R&D and manufacturing capabilities.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *